SinoMab Showcases Promising Preclinical Data for Novel Antibody in Alopecia and Vitiligo

The latest announcement is out from SinoMab Bioscience Ltd. ( (HK:3681) ).

SinoMab BioScience has presented preclinical data on its first-in-class humanised anti-gamma chain (gc) antibody hC2 at the 2026 Society for Investigative Dermatology meeting in Chicago, highlighting its potential as a differentiated biologic therapy for alopecia areata and vitiligo. In humanized animal models, hC2 significantly reduced hair loss and skin depigmentation, dampened T-cell infiltration and inflammatory markers, and showed favourable tolerability in primate toxicology studies, supporting its advancement through CMC optimisation toward an IND filing for alopecia areata targeted for late 2026, which could strengthen SinoMab’s position in the competitive autoimmune dermatology space.

By selectively modulating gc-dependent cytokine signalling rather than using the broader JAK inhibition approach, hC2 offers a distinct immunomodulatory mechanism that may appeal to clinicians and patients seeking targeted treatments with potentially different safety and efficacy profiles. Successful clinical development could expand SinoMab’s portfolio into high-need dermatology markets such as alopecia areata and vitiligo, enhancing its growth prospects and increasing its relevance among global players in autoimmune disease therapeutics.

More about SinoMab Bioscience Ltd.

SinoMab BioScience Limited is a Hong Kong–incorporated biopharmaceutical company focused on developing innovative antibody-based therapies for autoimmune and inflammatory diseases. Its in-house pipeline includes first-in-class humanised antibodies targeting key immune pathways, with a particular emphasis on dermatological and systemic autoimmune indications.

Average Trading Volume: 4,009,780

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.91B

Learn more about 3681 stock on TipRanks’ Stock Analysis page.